CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer

BMC Cancer

Table 1 Patient characteristics in the “Pilot-TNBC” cohort

Pt ID	Spec# 1	Spec# 2	Histology	Age range	Stage	Lehmann subtypes	(Neo)adjuvant chemo	Radiation	RFS (months)	OS (months)
1	Breast	Lung Met	IDC	60–69	II	BL2 → BL2	AC-T	Yes	34	113
2	Breast	Bone Met	IDC	50–59	II	LAR→LAR	AC	No	17	60
3	Breast	LN Met	IDC	40–49	II	BL1 → BL1	AC	No	39	92
4	LN	Liver Met	IDC	40–49	III	BL1 → LAR	Carbo/Taxol	Yes	10	20
5	Breast	Skin Met	IDC	30–39	III	M → M	AC	Unknown	2	9
6	Brain	Soft tissue Met	IDC	50–59	II	M → M	TAC	No	31	67
7	Breast	LN Met	IDC	50–59	I	BL1 → BL2	Declined	No	26	46
8	Endometrium	LN Met	IDC	30–39	III	M → LAR	TC	Unknown	11	58
9	Breast	Contralateral breast Met	ILC	40–49	II	LAR→BL2	AC-T	Yes	8	23
10	Breast	Brain Met	Metaplastic	50–59	II	BL1 → BL1	AC-T	Unknown	16	58

IDC invasive ductal carcinoma, LN lymph node, RFS relapse-free survival (surgery to first relapse), OS overall survival (surgery to death), ILC invasive lobular carcinoma, AC adriamycin/cyclophosphamide, AC-T adriamycin/cyclophosphamide - > paclitaxel, Carbo/taxol carboplatin/paclitaxel, TAC docetaxel/adriamycin/cyclophosphamide, TC docetaxel /cyclophosphamide, Met metastatic tumor, BL1 basal-like 1, BL2 basal-like 2, M mesenchymal, LAR luminal androgen receptor, Spec specimen

ISSN: 1471-2407